The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessment of subtype prevalence and the impact of HER2-directed therapy on emergency department (ED) utilization by real-world breast cancer patients.
 
Sandra Mayer
No Relationships to Disclose
 
Anna Pfarrhofer
No Relationships to Disclose
 
Sophie Neubauer
No Relationships to Disclose
 
Sabina Pasalic
No Relationships to Disclose
 
Georg Jeryczynski
No Relationships to Disclose
 
Maximilian Marhold
No Relationships to Disclose
 
Jutta Bergler-Klein
No Relationships to Disclose
 
Thorsten Fuereder
Honoraria - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Merck KGaA; MSD; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; BeiGene; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Invios; Invios; Janssen; Lilly; Merck KGaA; MSD; PharmaMar; Takeda
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Kura Oncology (Inst); Merck KGaA (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene; Merck KGaA; MSD
 
Filippo Cacioppo
No Relationships to Disclose
 
Anton Laggner
No Relationships to Disclose
 
Wilhelm Behringer
No Relationships to Disclose
 
Matthias Preusser
Honoraria - Abbvie; Adastra Pharmaceuticals; AstraZeneca; Bayer; BMJ Journals; Bristol-Myers Squibb; CMC Contrast; Daiichi Sankyo; Gan & Lee; Gerson Lehrman Group; GlaxoSmithKline; Lilly; Medahead; MedMedia; Merck Sharp & Dome; Mundipharma; Novartis; Roche; Sanofi; SERVIER; Telix Pharmaceuticals; Tocagen
Consulting or Advisory Role - AbbVie; Adastra Pharmaceuticals; AstraZeneca; Bayer; Bristol-Myers Squibb; CMC Contrast; Daiichi Sankyo/Astra Zeneca; Gan & Lee; Gerson Lehrman Group; GlaxoSmithKline; Lilly; Merck Sharp & Dome; Mundipharma; Novartis; Roche; Sanofi; SERVIER; Tocagen
Research Funding - AbbVie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Merck Sharp & Dohme; Novartis (Inst); Roche (Inst); Telix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Mundipharma; Roche; SERVIER
 
Rupert Bartsch
Honoraria - AstraZeneca; Daiicho; Lilly; Novartis; Pfizer; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi; Eisai; Lilly; MSD Oncology; MSD Oncology; Novartis; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Puma Biotechnology; Roche; Seagen
Research Funding - Daiichi (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo Europe GmbH; Pfizer; Pfizer; Roche; Roche
 
Christoph Minichsdorfer
Honoraria - Merck; MSD; Roche; Sandoz
Travel, Accommodations, Expenses - Merck; MSD; Roche